SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-23-032677
Filing Date
2023-05-26
Accepted
2023-05-26 17:49:15
Documents
2
Period of Report
2023-05-24

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3972
2 POA DOCUMENT poa.txt EX-24 3884
  Complete submission text file 0001209191-23-032677.txt   9367
Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Issuer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O CORTEXYME, INC. 269 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080
Business Address
McLoughlin Margaret (Reporting) CIK: 0001770823 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38890 | Film No.: 23970556